Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

被引：0
|
作者：
Andrew Rowland
Mafalda M Dias
Michael D Wiese
Ganessan Kichenadasse
Ross A McKinnon
Christos S Karapetis
Michael J Sorich
机构：
[1] School of Medicine,Department of Clinical Pharmacology
[2] Flinders University,undefined
[3] Flinders Centre for Innovation in Cancer,undefined
[4] School of Medicine,undefined
[5] Flinders University,undefined
[6] School of Pharmacy and Medical Sciences,undefined
[7] University of South Australia,undefined
来源：
British Journal of Cancer | 2015年 / 113卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1635 / 1635
相关论文
共 50 条
  • [1] Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
    Rowland, Andrew
    Dias, Mafalda M.
    Wiese, Michael D.
    Kichenadasse, Ganessan
    McKinnon, Ross A.
    Karapetis, Christos S.
    Sorich, Michael J.
    BRITISH JOURNAL OF CANCER, 2015, 113 (11) : 1635 - 1635
  • [2] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
    Rowland, A.
    Dias, M. M.
    Wiese, M. D.
    Kichenadasse, G.
    McKinnon, R. A.
    Karapetis, C. S.
    Sorich, M. J.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1888 - 1894
  • [3] Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
    A Rowland
    M M Dias
    M D Wiese
    G Kichenadasse
    R A McKinnon
    C S Karapetis
    M J Sorich
    British Journal of Cancer, 2015, 112 : 1888 - 1894
  • [4] Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Xiaona Lu
    Yuyao Li
    Yue Li
    Xuemei Zhang
    Jia Shi
    Hai Feng
    Zhuo Yu
    Yueqiu Gao
    BMC Cancer, 23
  • [5] Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Lu, Xiaona
    Li, Yuyao
    Li, Yue
    Zhang, Xuemei
    Shi, Jia
    Feng, Hai
    Yu, Zhuo
    Gao, Yueqiu
    BMC CANCER, 2023, 23 (01)
  • [6] Treatment of extended RAS/ BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations
    Voutsadakis, Ioannis A.
    PHARMACOGENOMICS, 2025,
  • [7] BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer
    Chen Mao
    Ru-Yan Liao
    Qing Chen
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 1293 - 1294
  • [8] BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer
    Mao, Chen
    Liao, Ru-Yan
    Chen, Qing
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (08) : 1293 - 1294
  • [9] Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component
    Moretto, Roberto
    Morano, Federica
    Ongaro, Elena
    Rossini, Daniele
    Pietrantonio, Filippo
    Casagrande, Mariaelena
    Antoniotti, Carlotta
    Corallo, Salvatore
    Marmorino, Federica
    Cortiula, Francesco
    Nichetti, Federico
    Borelli, Beatrice
    Zucchelli, Gemma
    Boccaccino, Alessandra
    Masi, Gianluca
    de Braud, Filippo
    Falcone, Alfredo
    Cremolini, Chiara
    CLINICAL COLORECTAL CANCER, 2019, 18 (02) : 116 - 124
  • [10] Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis
    Li, Dandan
    Fu, Qiang
    Li, Man
    Li, Jun
    Yin, Can
    Zhao, Jin
    Li, Feng
    FUTURE ONCOLOGY, 2017, 13 (12) : 1115 - 1127
12345